PPA
SIOX

Parametric Portfolio Associates’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Parametric Portfolio Associates’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,574
Closed -$17K – 3964
2018
Q1 		$17K Buy
1,574
+211
+15% +$3.39K ﹤0.01% 3926
2017
Q4 		$57K Buy
+1,363
New +$61.2K ﹤0.01% 3862

Other funds holding SIOX

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Parametric Portfolio Associates's SIOX Position: Q2 2018 in Review

Parametric Portfolio Associates sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2018, closing a stake of 1,574 shares — an estimated $17K sold.

Parametric Portfolio Associates first reported a position in SIOX in Q4 2017 and held it in 2 quarters. The position peaked at $57K in Q4 2017. 71 funds tracked by Wall St. Rank hold SIOX as of Q2 2018.

  • Parametric Portfolio Associates reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Parametric Portfolio Associates sold 1,574 Sio Gene Therapies Inc. Common Stock shares in Q2 2018, an estimated $17K.
  • Parametric Portfolio Associates first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2017 and held it in 2 quarters.
  • Parametric Portfolio Associates's Sio Gene Therapies Inc. Common Stock position peaked at $57K in Q4 2017.
  • 71 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2018.

Based on Parametric Portfolio Associates's 13F filing for Q2 2018, filed 13 Aug 2018.